Clinical trials: Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- DENALI-1 (NCT06682793)
- Testing
- A2B395, xT CDx with HLA-LOH assay
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- A2 Biotherapeutics Inc.
Squamous Non-small Cell Lung Cancer
A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
This study aims to characterize the profile and outcomes for patients with Squamous Cell Carcinoma of the Lung (SqCC) who progress on 1L pembrolizumab in combination with platinum based chemotherapy and receive afatinib as second…
- Trial name
- NCT04552535
- Testing
- Second line (2L) afatinib, Second line chemotherapy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Boehringer Ingelheim
Non-Small Cell Lung Cancer
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally…
- Trial name
- TROPION-Lung10 (NCT06357533)
- Testing
- Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab
- Where
- 290 sites in United States, Australia and 19 more
- Volunteers
- 675 people
- Sponsor
- AstraZeneca
Breast Cancer, Colorectal Cancer
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody.
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT04244552
- Testing
- ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
- Where
- 19 sites in United States
- Volunteers
- 87 people
- Sponsor
- Atreca, Inc.
Advanced Castrate-resistant Prostate Cancer CRPC, Squamous Non-Small Cell Lung Cancer sqNSCLC
AZD8186 First Time In Patient Ascending Dose Study
This is a phase I, open-label, multicentre study of AZD8186 administered orally in patients with advanced castrate-resistant prostate cancer (CRPC), squamous non-small cell lung cancer (sqNSCLC), triple negative breast cancer…
- Conditions
- Advanced Castrate-resistant Prostate Cancer CRPC, Squamous Non-Small Cell Lung Cancer sqNSCLC, Triple Negative Breast Cancer TNBC
- Trial name
- NCT01884285
- Testing
- Part A: AZD8186 monotherapy, Part B: AZD8186 monotherapy, Part C1: Abiraterone acetate combination with AZD8186
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 147 people
- Sponsor
- AstraZeneca
Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer, Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer
Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer
To determine the rate of pathologic complete responses (pCR) at the time of definitive surgical resection of non-small cell lung cancer (NSCLC)
- Trial name
- NCT01860040
- Testing
- Cisplatin, Pemetrexed, Gemcitabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Western Regional Medical Center
Carcinoma, Non-Small Cell Lung
Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer
AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC).
- Trial name
- NCT00768755
- Testing
- axitinib, chemotherapy
- Where
- 52 sites in United States, Italy and 9 more
- Volunteers
- 180 people
- Sponsor
- Pfizer
Non-squamous Non-small Cell Lung Cancer
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
This trial is a multicenter, open-label, Phase II clinical study to explore the efficacy and safety of BL-M07D1 in combination with pembrolizumab in patients with locally advanced or metastatic HER2-overexpressing non-squamous…
- Trial name
- NCT07264816
- Testing
- BL-M07D1, Pembrolizumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with or without gefitinib in treating unresectable stage III non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00020709
- Testing
- cisplatin, docetaxel, etoposide
- Where
- United States
- Volunteers
- 840 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00268255
- Testing
- gefitinib, adjuvant therapy, enzyme inhibitor therapy
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Non-small Cell Lung Cancer, Lung Cancer
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
The purpose of this study is to provide brigatinib for those patients with locally advanced and/or metastatic patients with ALK+ NSCLC on an expanded access basis due to their inability to meet eligibility criteria for on-going…
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma
- Trial name
- NCT02784158
- Testing
- Brigatinib
- Where
- 3 sites in United States
- Sponsor
- Ariad Pharmaceuticals
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
This randomized phase I/II trial studies the side effects, best way to give, and best dose of erlotinib and bevacizumab when given with cetuximab and how well giving erlotinib and cetuximab together with or without bevacizumab…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer
- Trial name
- NCT00101348
- Testing
- erlotinib hydrochloride, cetuximab, bevacizumab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer
The purpose of the trial is to determine the rate of improvement in objective tumor response, following the addition of ranpirnase to ongoing pemetrexed-carboplatin chemotherapy, for patients with SD or PR following 2 cycles of…
- Trial name
- NCT01184287
- Testing
- Ranpirnase
- Where
- 6 sites in United States
- Sponsor
- Tamir Biotechnology, Inc.
Non-Small Cell Lung Cancer
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
The purpose of this study is to compare the overall survival of patients receiving E7080 + Best Supportive Care (BSC) with those receiving placebo + Best Supportive Care.
- Trial name
- NCT01529112
- Testing
- Lenvatinib, BSC
- Where
- 50 sites in United States, Belgium and 5 more
- Volunteers
- 135 people
- Sponsor
- Eisai Inc.
Melanoma Stage IV, Head and Neck Squamous Cell Carcinoma
Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders
This is a single-arm, single-center, open-label, phase IIa study evaluating the safety, feasibility and efficacy of Faecal Microbiota Transplant (FMT) to cancer patients not responding to ICI therapy, using ICI-responders as…
- Conditions
- Melanoma Stage IV, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, MSI-High
- Trial name
- MITRIC (NCT05286294)
- Testing
- Fecal Microbiota Transplant (FMT)
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Non Small Cell Lung Cancer
Atezolizumab Plus Bevacizumab in First Line NSCLC Patients
This is a multi-center phase II clinical trial of atezolizumab in combination with bevacizumab as first line treatment for locally advanced or metastasic high-intermediate tumour mutation burden selected NSCLC patients.
- Trial name
- TELMA (NCT03836066)
- Testing
- Atezolizumab-Bevacizumab
- Where
- 25 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Fundación GECP
Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma of the Lung
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
This is a randomized phase II study assessing the activity of single agent chemotherapy combined with nivolumab (Arm A) compared to single agent chemotherapy alone (Arm B) in squamous or non-squamous NSCLC subjects with primary…
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma of the Lung, Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT03041181
- Testing
- Docetaxel, Nivolumab, Gemcitabine
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- Nasser Hanna, M.D.
Non Small Cell Lung Cancer
Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer
In this trial, subjects with chemo-naive advanced non-small cell lung cancer (NSCLC) were assigned to chemotherapy using a genomic-based predictor for platinum sensitivity.
- Trial name
- TOP0602 (NCT00509366)
- Testing
- Cisplatin & Gemcitabine, Cisplatin & Pemetrexed, Docetaxel & Gemcitabine
- Where
- 8 sites in United States
- Volunteers
- 101 people
- Sponsor
- Duke University
Lung Cancer
Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT00960999
- Testing
- Single-fraction stereotactic body radiation therapy (SBRT), Multiple-fraction stereotactic body radiation therapy (SBRT)
- Where
- 38 sites in United States, Canada
- Volunteers
- 94 people
- Sponsor
- Radiation Therapy Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.